Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Identifieur interne : 003681 ( PubMed/Corpus ); précédent : 003680; suivant : 003682Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Auteurs : Timothy P. Hughes ; Andreas Hochhaus ; Hagop M. Kantarjian ; Francisco Cervantes ; François Guilhot ; Dietger Niederwieser ; Philipp D. Le Coutre ; Gianantonio Rosti ; Gert Ossenkoppele ; Clarisse Lobo ; Hirohiko Shibayama ; Xiaolin Fan ; Hans D. Menssen ; Charisse Kemp ; Richard A. Larson ; Giuseppe SaglioSource :
- Haematologica [ 1592-8721 ] ; 2014.
English descriptors
- KwdEn :
- Antineoplastic Agents (administration & dosage), Antineoplastic Agents (adverse effects), Benzamides (administration & dosage), Benzamides (adverse effects), Drug Substitution, Follow-Up Studies, Humans, Imatinib Mesylate, Leukemia, Myeloid, Chronic-Phase (drug therapy), Piperazines (administration & dosage), Piperazines (adverse effects), Protein Kinase Inhibitors (administration & dosage), Protein Kinase Inhibitors (adverse effects), Pyrimidines (administration & dosage), Pyrimidines (adverse effects), Treatment Failure, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Benzamides, Piperazines, Protein Kinase Inhibitors, Pyrimidines.
- chemical , adverse effects : Antineoplastic Agents, Benzamides, Piperazines, Protein Kinase Inhibitors, Pyrimidines.
- drug therapy : Leukemia, Myeloid, Chronic-Phase.
- Drug Substitution, Follow-Up Studies, Humans, Imatinib Mesylate, Treatment Failure, Treatment Outcome.
Abstract
In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase, more patients had suboptimal response or treatment failure on front-line imatinib than on nilotinib. Patients with suboptimal response/treatment failure on imatinib 400 mg once or twice daily or nilotinib 300 mg twice daily could enter an extension study to receive nilotinib 400 mg twice daily. After a 19-month median follow up, the safety profile of nilotinib 400 mg twice daily in patients switching from imatinib (n=35) was consistent with previous reports, and few new adverse events occurred in patients escalating from nilotinib 300 mg twice daily (n=19). Of patients previously treated with imatinib or nilotinib 300 mg twice daily, respectively, 15 of 26 (58%) and 2 of 6 (33%) without complete cytogenetic response at extension study entry, and 11 of 34 (32%) and 7 of 18 (39%) without major molecular response at extension study entry, achieved these responses at any time on nilotinib 400 mg twice daily. Estimated 18-month rates of freedom from progression and overall survival after entering the extension study were lower for patients switched from imatinib (85% and 87%, respectively) versus nilotinib 300 mg twice daily (95% and 94%, respectively). Nilotinib dose escalation was generally well tolerated and improved responses in about one-third of patients with suboptimal response/treatment failure. Switch to nilotinib improved responses in some patients with suboptimal response/treatment failure on imatinib, but many did not achieve complete cytogenetic response (clinicaltrials.gov identifiers: 00718263, 00471497 - extension).
DOI: 10.3324/haematol.2013.091272
PubMed: 24532039
Links to Exploration step
pubmed:24532039Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.</title><author><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P" last="Hughes">Timothy P. Hughes</name><affiliation><nlm:affiliation>South Australian Health and Medical Research Institute, University of Adelaide, Australia Division of Haematology and Centre for Cancer Biology, SA Pathology, Adelaide, Australia timothy.hughes@health.sa.gov.au.</nlm:affiliation></affiliation></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name><affiliation><nlm:affiliation>Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name><affiliation><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cervantes, Francisco" sort="Cervantes, Francisco" uniqKey="Cervantes F" first="Francisco" last="Cervantes">Francisco Cervantes</name><affiliation><nlm:affiliation>IDIBAPS, University of Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="François" last="Guilhot">François Guilhot</name><affiliation><nlm:affiliation>Inserm CIC 0802, CHU de Poitiers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name><affiliation><nlm:affiliation>Division of Hematology and Oncology, University of Leipzig, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Le Coutre, Philipp D" sort="Le Coutre, Philipp D" uniqKey="Le Coutre P" first="Philipp D" last="Le Coutre">Philipp D. Le Coutre</name><affiliation><nlm:affiliation>Charité - Universitätsmedizin Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name><affiliation><nlm:affiliation>University of Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ossenkoppele, Gert" sort="Ossenkoppele, Gert" uniqKey="Ossenkoppele G" first="Gert" last="Ossenkoppele">Gert Ossenkoppele</name><affiliation><nlm:affiliation>VU University Medical Center, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lobo, Clarisse" sort="Lobo, Clarisse" uniqKey="Lobo C" first="Clarisse" last="Lobo">Clarisse Lobo</name><affiliation><nlm:affiliation>HEMORIO, Rio de Janeiro, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Shibayama, Hirohiko" sort="Shibayama, Hirohiko" uniqKey="Shibayama H" first="Hirohiko" last="Shibayama">Hirohiko Shibayama</name><affiliation><nlm:affiliation>Osaka University Graduate School of Medicine, Osaka, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Fan, Xiaolin" sort="Fan, Xiaolin" uniqKey="Fan X" first="Xiaolin" last="Fan">Xiaolin Fan</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Menssen, Hans D" sort="Menssen, Hans D" uniqKey="Menssen H" first="Hans D" last="Menssen">Hans D. Menssen</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Kemp, Charisse" sort="Kemp, Charisse" uniqKey="Kemp C" first="Charisse" last="Kemp">Charisse Kemp</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A" last="Larson">Richard A. Larson</name><affiliation><nlm:affiliation>The University of Chicago, IL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name><affiliation><nlm:affiliation>University of Turin, Orbassano, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24532039</idno><idno type="pmid">24532039</idno><idno type="doi">10.3324/haematol.2013.091272</idno><idno type="wicri:Area/PubMed/Corpus">003681</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003681</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.</title><author><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P" last="Hughes">Timothy P. Hughes</name><affiliation><nlm:affiliation>South Australian Health and Medical Research Institute, University of Adelaide, Australia Division of Haematology and Centre for Cancer Biology, SA Pathology, Adelaide, Australia timothy.hughes@health.sa.gov.au.</nlm:affiliation></affiliation></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name><affiliation><nlm:affiliation>Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name><affiliation><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cervantes, Francisco" sort="Cervantes, Francisco" uniqKey="Cervantes F" first="Francisco" last="Cervantes">Francisco Cervantes</name><affiliation><nlm:affiliation>IDIBAPS, University of Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="François" last="Guilhot">François Guilhot</name><affiliation><nlm:affiliation>Inserm CIC 0802, CHU de Poitiers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name><affiliation><nlm:affiliation>Division of Hematology and Oncology, University of Leipzig, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Le Coutre, Philipp D" sort="Le Coutre, Philipp D" uniqKey="Le Coutre P" first="Philipp D" last="Le Coutre">Philipp D. Le Coutre</name><affiliation><nlm:affiliation>Charité - Universitätsmedizin Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name><affiliation><nlm:affiliation>University of Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ossenkoppele, Gert" sort="Ossenkoppele, Gert" uniqKey="Ossenkoppele G" first="Gert" last="Ossenkoppele">Gert Ossenkoppele</name><affiliation><nlm:affiliation>VU University Medical Center, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lobo, Clarisse" sort="Lobo, Clarisse" uniqKey="Lobo C" first="Clarisse" last="Lobo">Clarisse Lobo</name><affiliation><nlm:affiliation>HEMORIO, Rio de Janeiro, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Shibayama, Hirohiko" sort="Shibayama, Hirohiko" uniqKey="Shibayama H" first="Hirohiko" last="Shibayama">Hirohiko Shibayama</name><affiliation><nlm:affiliation>Osaka University Graduate School of Medicine, Osaka, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Fan, Xiaolin" sort="Fan, Xiaolin" uniqKey="Fan X" first="Xiaolin" last="Fan">Xiaolin Fan</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Menssen, Hans D" sort="Menssen, Hans D" uniqKey="Menssen H" first="Hans D" last="Menssen">Hans D. Menssen</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Kemp, Charisse" sort="Kemp, Charisse" uniqKey="Kemp C" first="Charisse" last="Kemp">Charisse Kemp</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A" last="Larson">Richard A. Larson</name><affiliation><nlm:affiliation>The University of Chicago, IL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name><affiliation><nlm:affiliation>University of Turin, Orbassano, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Haematologica</title><idno type="eISSN">1592-8721</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (administration & dosage)</term><term>Antineoplastic Agents (adverse effects)</term><term>Benzamides (administration & dosage)</term><term>Benzamides (adverse effects)</term><term>Drug Substitution</term><term>Follow-Up Studies</term><term>Humans</term><term>Imatinib Mesylate</term><term>Leukemia, Myeloid, Chronic-Phase (drug therapy)</term><term>Piperazines (administration & dosage)</term><term>Piperazines (adverse effects)</term><term>Protein Kinase Inhibitors (administration & dosage)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Pyrimidines (administration & dosage)</term><term>Pyrimidines (adverse effects)</term><term>Treatment Failure</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term><term>Benzamides</term><term>Piperazines</term><term>Protein Kinase Inhibitors</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Benzamides</term><term>Piperazines</term><term>Protein Kinase Inhibitors</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Myeloid, Chronic-Phase</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Substitution</term><term>Follow-Up Studies</term><term>Humans</term><term>Imatinib Mesylate</term><term>Treatment Failure</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase, more patients had suboptimal response or treatment failure on front-line imatinib than on nilotinib. Patients with suboptimal response/treatment failure on imatinib 400 mg once or twice daily or nilotinib 300 mg twice daily could enter an extension study to receive nilotinib 400 mg twice daily. After a 19-month median follow up, the safety profile of nilotinib 400 mg twice daily in patients switching from imatinib (n=35) was consistent with previous reports, and few new adverse events occurred in patients escalating from nilotinib 300 mg twice daily (n=19). Of patients previously treated with imatinib or nilotinib 300 mg twice daily, respectively, 15 of 26 (58%) and 2 of 6 (33%) without complete cytogenetic response at extension study entry, and 11 of 34 (32%) and 7 of 18 (39%) without major molecular response at extension study entry, achieved these responses at any time on nilotinib 400 mg twice daily. Estimated 18-month rates of freedom from progression and overall survival after entering the extension study were lower for patients switched from imatinib (85% and 87%, respectively) versus nilotinib 300 mg twice daily (95% and 94%, respectively). Nilotinib dose escalation was generally well tolerated and improved responses in about one-third of patients with suboptimal response/treatment failure. Switch to nilotinib improved responses in some patients with suboptimal response/treatment failure on imatinib, but many did not achieve complete cytogenetic response (clinicaltrials.gov identifiers: 00718263, 00471497 - extension).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24532039</PMID><DateCreated><Year>2014</Year><Month>07</Month><Day>02</Day></DateCreated><DateCompleted><Year>2015</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Haematologica</Title><ISOAbbreviation>Haematologica</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.</ArticleTitle><Pagination><MedlinePgn>1204-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2013.091272</ELocationID><Abstract><AbstractText>In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase, more patients had suboptimal response or treatment failure on front-line imatinib than on nilotinib. Patients with suboptimal response/treatment failure on imatinib 400 mg once or twice daily or nilotinib 300 mg twice daily could enter an extension study to receive nilotinib 400 mg twice daily. After a 19-month median follow up, the safety profile of nilotinib 400 mg twice daily in patients switching from imatinib (n=35) was consistent with previous reports, and few new adverse events occurred in patients escalating from nilotinib 300 mg twice daily (n=19). Of patients previously treated with imatinib or nilotinib 300 mg twice daily, respectively, 15 of 26 (58%) and 2 of 6 (33%) without complete cytogenetic response at extension study entry, and 11 of 34 (32%) and 7 of 18 (39%) without major molecular response at extension study entry, achieved these responses at any time on nilotinib 400 mg twice daily. Estimated 18-month rates of freedom from progression and overall survival after entering the extension study were lower for patients switched from imatinib (85% and 87%, respectively) versus nilotinib 300 mg twice daily (95% and 94%, respectively). Nilotinib dose escalation was generally well tolerated and improved responses in about one-third of patients with suboptimal response/treatment failure. Switch to nilotinib improved responses in some patients with suboptimal response/treatment failure on imatinib, but many did not achieve complete cytogenetic response (clinicaltrials.gov identifiers: 00718263, 00471497 - extension).</AbstractText><CopyrightInformation>Copyright© Ferrata Storti Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Timothy P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>South Australian Health and Medical Research Institute, University of Adelaide, Australia Division of Haematology and Centre for Cancer Biology, SA Pathology, Adelaide, Australia timothy.hughes@health.sa.gov.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochhaus</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarjian</LastName><ForeName>Hagop M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervantes</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IDIBAPS, University of Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilhot</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm CIC 0802, CHU de Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niederwieser</LastName><ForeName>Dietger</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, University of Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>le Coutre</LastName><ForeName>Philipp D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Charité - Universitätsmedizin Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosti</LastName><ForeName>Gianantonio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Gert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobo</LastName><ForeName>Clarisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>HEMORIO, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibayama</LastName><ForeName>Hirohiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Xiaolin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menssen</LastName><ForeName>Hans D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemp</LastName><ForeName>Charisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>The University of Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saglio</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Turin, Orbassano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00471497</AccessionNumber><AccessionNumber>NCT00718263</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Haematologica</MedlineTA><NlmUniqueID>0417435</NlmUniqueID><ISSNLinking>0390-6078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498826">4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2005 Feb;7(2):129-41</RefSource><PMID Version="1">15710326</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Dec 1;112(12):4437-44</RefSource><PMID Version="1">18716134</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2009 Feb 1;115(3):551-60</RefSource><PMID Version="1">19117345</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Mar 5;113(10):2154-60</RefSource><PMID Version="1">19060245</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2009 Aug 15;115(16):3709-18</RefSource><PMID Version="1">19517462</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Dec 10;27(35):6041-51</RefSource><PMID Version="1">19884523</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jan 20;28(3):424-30</RefSource><PMID Version="1">20008622</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2010 Jul;89(7):725-31</RefSource><PMID Version="1">20179930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2010 Jun;95(6):908-13</RefSource><PMID Version="1">20145273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jun 17;362(24):2251-9</RefSource><PMID Version="1">20525993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Jan 27;117(4):1141-5</RefSource><PMID Version="1">21098399</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2011 Sep;12(9):841-51</RefSource><PMID Version="1">21856226</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Jan 1;118(1):118-26</RefSource><PMID Version="1">21732337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Mar 1;118(5):1181-91</RefSource><PMID Version="1">22038681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2012 May;26(5):959-62</RefSource><PMID Version="1">22157807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2012 Jun;26(6):1189-94</RefSource><PMID Version="1">22076466</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2012 Oct;26(10):2172-5</RefSource><PMID Version="1">22504141</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2012 Oct;26(10):2197-203</RefSource><PMID Version="1">22699418</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Jan;27(1):107-12</RefSource><PMID Version="1">22763385</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Haematologica. 2014 Jul;99(7):1123-4</RefSource><PMID Version="1">24986871</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015466" MajorTopicYN="N">Leukemia, Myeloid, Chronic-Phase</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4077082</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24532039</ArticleId><ArticleId IdType="pii">haematol.2013.091272</ArticleId><ArticleId IdType="doi">10.3324/haematol.2013.091272</ArticleId><ArticleId IdType="pmc">PMC4077082</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003681 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003681 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24532039
|texte= Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24532039" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |